Cyclacel Continues AML Trial Of Sapacitabine Despite Futility Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology biotech is plowing ahead with its late-stage study of sapacitabine, despite unfavorable findings during an interim analysis.